ATC Group: L01FA01 Rituximab

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FA01 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FA CD20 (Clusters of Differentiation 20) inhibitors
5 L01FA01 Rituximab

Active ingredients in L01FA01

Active Ingredient Description
Rituximab

Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas.

Related product monographs

Title Information Source Document Type  
BLITZIMA Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
REDDITUX Concentrate for solution for infusion Health Products Regulatory Authority (ZA) MPI, Generic
RITEMVIA Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
RITUXAN Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
RUXIENCE Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
TRUXIMA Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Cyprus (CY)

Hong Kong (HK)

Japan (JP)

Netherlands (NL)

Singapore (SG)

South Africa (ZA)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.